View in EDS

Prospective Evaluation of Non-Small Cell Lung Cancer Radiation Therapy Treatment Interruptions in a Large Statewide Quality Collaborative.

Saved in:
Bibliographic Details
Title: Prospective Evaluation of Non-Small Cell Lung Cancer Radiation Therapy Treatment Interruptions in a Large Statewide Quality Collaborative.
Authors: Elaimy, A.L.1 (AUTHOR), Schipper, M.1,2 (AUTHOR), Yin, H.1,2 (AUTHOR), Matuszak, M.M.1 (AUTHOR), Dominello, M.M.3 (AUTHOR), Bergsma, D.P.1 (AUTHOR), Paximadis, P.A.4 (AUTHOR), Zaki, M.5 (AUTHOR), Kestin, L.L.6 (AUTHOR), Hayman, J.A.1 (AUTHOR), Dragovic, A.F.1 (AUTHOR), Jolly, S.1 (AUTHOR)
Source: International Journal of Radiation Oncology, Biology, Physics. 2024 Supplement, Vol. 120 Issue 2, pe19-e19. 1p.
Subjects: Non-small-cell lung carcinoma, Radiotherapy, Cancer treatment, Therapeutics, Radiation doses
Abstract: For patients receiving radiation therapy for non-small cell lung cancer (NSCLC), unplanned interruptions prolong the treatment course and may be associated with adverse outcomes. However, little is known regarding patient and treatment planning characteristics that contribute to interruptions. The purpose of this study was to characterize the frequency, type duration and predictors of interruptions in radiation therapy in patients with NSCLC treated with conventional fractionation throughout a statewide quality collaborative. Clinical and dosimetric data as well as frequency and duration of treatment interruptions (> or ≤ 5 days) were prospectively collected by 29 institutions within the Michigan Radiation Oncology Quality Consortium between 2012 and 2024 for patients with NSCLC treated with conventional fractionation using a physician-assessed survey. In version 1 of the survey (2012 to August 2017) data regarding toxicity breaks only were recorded. In version 2 of the survey (September 2017 to 2024) data regarding both any treatment interruption and toxicity breaks were recorded. We modeled the influence of patient, disease and treatment characteristics including mean and other radiation dose metrics for lung, heart and esophagus on the odds of any treatment interruption using multivariate logistic regression. Toxicity breaks were reported in 9% (131/1476) of patients and toxicity breaks greater than 5 days were reported in 3.5% (51/1476) of patients. Any treatment interruption was reported in 18% (154/867) of patients and toxicity breaks were reported in 6% (56/867) of patients enrolled during version 2 of the survey. Stepwise modeling identified a MV model for any toxicity break including heart V10Gy (OR per 10% increase = 1.16, p = 0.001), concurrent chemotherapy (Yes vs No = 2.67, p = 0.024) and ECOG (OR per 1 point increase = 1.91, p<0.001). In this model, all of the other tested heart dose metrics (mean and V10-V60) were significant predictors for any toxicity break and mean esophagus dose was not a significant predictor for any toxicity break. Stepwise modeling identified a MV model for toxicity break > 5 days including heart V10Gy (OR per 10% increase = 1.12, p<0.001) and ECOG (OR per 1 point increase = 1.87, p <0.001). Additionally, stepwise modeling selected smoking status (p = 0.05), ECOG (p<0.01) and lung V10Gy (p<0.01) as jointly significant predictors of any toxicity related break. PTV volume was not associated with treatment interruptions in all 3 models. Both clinical and dosimetric factors are associated with treatment interruptions in patients with NSCLC undergoing conventional fractionation. Efforts should be made to identify patients at increased risk of interruptions to optimize treatment planning and minimize toxicity. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 179876736
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prospective Evaluation of Non-Small Cell Lung Cancer Radiation Therapy Treatment Interruptions in a Large Statewide Quality Collaborative.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Elaimy%2C+A%2EL%2E%22&quot;&gt;Elaimy, A.L.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Schipper%2C+M%2E%22&quot;&gt;Schipper, M.&lt;/searchLink&gt;&lt;relatesTo&gt;1,2&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yin%2C+H%2E%22&quot;&gt;Yin, H.&lt;/searchLink&gt;&lt;relatesTo&gt;1,2&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Matuszak%2C+M%2EM%2E%22&quot;&gt;Matuszak, M.M.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dominello%2C+M%2EM%2E%22&quot;&gt;Dominello, M.M.&lt;/searchLink&gt;&lt;relatesTo&gt;3&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bergsma%2C+D%2EP%2E%22&quot;&gt;Bergsma, D.P.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Paximadis%2C+P%2EA%2E%22&quot;&gt;Paximadis, P.A.&lt;/searchLink&gt;&lt;relatesTo&gt;4&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zaki%2C+M%2E%22&quot;&gt;Zaki, M.&lt;/searchLink&gt;&lt;relatesTo&gt;5&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kestin%2C+L%2EL%2E%22&quot;&gt;Kestin, L.L.&lt;/searchLink&gt;&lt;relatesTo&gt;6&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hayman%2C+J%2EA%2E%22&quot;&gt;Hayman, J.A.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dragovic%2C+A%2EF%2E%22&quot;&gt;Dragovic, A.F.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jolly%2C+S%2E%22&quot;&gt;Jolly, S.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22International+Journal+of+Radiation+Oncology%2C+Biology%2C+Physics%22&quot;&gt;International Journal of Radiation Oncology, Biology, Physics&lt;/searchLink&gt;. 2024 Supplement, Vol. 120 Issue 2, pe19-e19. 1p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Non-small-cell+lung+carcinoma%22&quot;&gt;Non-small-cell lung carcinoma&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Radiotherapy%22&quot;&gt;Radiotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cancer+treatment%22&quot;&gt;Cancer treatment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Therapeutics%22&quot;&gt;Therapeutics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Radiation+doses%22&quot;&gt;Radiation doses&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: For patients receiving radiation therapy for non-small cell lung cancer (NSCLC), unplanned interruptions prolong the treatment course and may be associated with adverse outcomes. However, little is known regarding patient and treatment planning characteristics that contribute to interruptions. The purpose of this study was to characterize the frequency, type duration and predictors of interruptions in radiation therapy in patients with NSCLC treated with conventional fractionation throughout a statewide quality collaborative. Clinical and dosimetric data as well as frequency and duration of treatment interruptions (&gt; or ≤ 5 days) were prospectively collected by 29 institutions within the Michigan Radiation Oncology Quality Consortium between 2012 and 2024 for patients with NSCLC treated with conventional fractionation using a physician-assessed survey. In version 1 of the survey (2012 to August 2017) data regarding toxicity breaks only were recorded. In version 2 of the survey (September 2017 to 2024) data regarding both any treatment interruption and toxicity breaks were recorded. We modeled the influence of patient, disease and treatment characteristics including mean and other radiation dose metrics for lung, heart and esophagus on the odds of any treatment interruption using multivariate logistic regression. Toxicity breaks were reported in 9% (131/1476) of patients and toxicity breaks greater than 5 days were reported in 3.5% (51/1476) of patients. Any treatment interruption was reported in 18% (154/867) of patients and toxicity breaks were reported in 6% (56/867) of patients enrolled during version 2 of the survey. Stepwise modeling identified a MV model for any toxicity break including heart V10Gy (OR per 10% increase = 1.16, p = 0.001), concurrent chemotherapy (Yes vs No = 2.67, p = 0.024) and ECOG (OR per 1 point increase = 1.91, p&lt;0.001). In this model, all of the other tested heart dose metrics (mean and V10-V60) were significant predictors for any toxicity break and mean esophagus dose was not a significant predictor for any toxicity break. Stepwise modeling identified a MV model for toxicity break &gt; 5 days including heart V10Gy (OR per 10% increase = 1.12, p&lt;0.001) and ECOG (OR per 1 point increase = 1.87, p &lt;0.001). Additionally, stepwise modeling selected smoking status (p = 0.05), ECOG (p&lt;0.01) and lung V10Gy (p&lt;0.01) as jointly significant predictors of any toxicity related break. PTV volume was not associated with treatment interruptions in all 3 models. Both clinical and dosimetric factors are associated with treatment interruptions in patients with NSCLC undergoing conventional fractionation. Efforts should be made to identify patients at increased risk of interruptions to optimize treatment planning and minimize toxicity. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=179876736
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ijrobp.2024.07.1818
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: e19
    Subjects:
      – SubjectFull: Non-small-cell lung carcinoma
        Type: general
      – SubjectFull: Radiotherapy
        Type: general
      – SubjectFull: Cancer treatment
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: Radiation doses
        Type: general
    Titles:
      – TitleFull: Prospective Evaluation of Non-Small Cell Lung Cancer Radiation Therapy Treatment Interruptions in a Large Statewide Quality Collaborative.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Elaimy, A.L.
      – PersonEntity:
          Name:
            NameFull: Schipper, M.
      – PersonEntity:
          Name:
            NameFull: Yin, H.
      – PersonEntity:
          Name:
            NameFull: Matuszak, M.M.
      – PersonEntity:
          Name:
            NameFull: Dominello, M.M.
      – PersonEntity:
          Name:
            NameFull: Bergsma, D.P.
      – PersonEntity:
          Name:
            NameFull: Paximadis, P.A.
      – PersonEntity:
          Name:
            NameFull: Zaki, M.
      – PersonEntity:
          Name:
            NameFull: Kestin, L.L.
      – PersonEntity:
          Name:
            NameFull: Hayman, J.A.
      – PersonEntity:
          Name:
            NameFull: Dragovic, A.F.
      – PersonEntity:
          Name:
            NameFull: Jolly, S.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 10
              Text: 2024 Supplement
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 03603016
          Numbering:
            – Type: volume
              Value: 120
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: International Journal of Radiation Oncology, Biology, Physics
              Type: main
ResultId 1